Rogers Jason H, Rocha-Singh Krishna J
Division of Cardiovascular Medicine, University of California, Davis Medical Center, 4860 Y Street, Suite #2820, Sacramento, CA, 95817, USA,
Curr Treat Options Cardiovasc Med. 2012 Apr;14(2):193-202. doi: 10.1007/s11936-012-0171-z.
Erectile dysfunction (ED) is an important clinical condition that affects a significant proportion of men. Although there are many etiologies for ED, many cases have a vascular basis that is related to inadequate arterial inflow, veno-occlusive dysfunction, or abnormalities in smooth muscle (cavernosal tissue) relaxation. These vascular abnormalities can exist in isolation or combination. Since the advent of phosphodiesterase-5 inhibitor (PDE5i) therapy, the initial management of ED in most cases consists of a brief medical evaluation followed by a trial of PDE5i therapy. However, up to 50% of men have an inadequate response to PDE5i therapy and discontinue therapy. Subsequent therapies for ED are increasingly invasive, including penile injection of vasodilators, vacuum pumps, and penile implants. With increased awareness of ED among clinicians and the growing mechanistic link between ED and atherosclerotic vascular disease, there has been renewed interest in the diagnosis and management of arteriogenic ED. Prior reports in the 1980s described the existence of arterial inflow lesions in patients with ED, and there are a modest number of reports describing the feasibility of revascularization with balloon angioplasty. Despite initial clinical success, enthusiasm for this technique waned, presumably because ED frequently recurred due to restenosis and lack of small vessel endovascular therapies. Recent investigation and the availability of newer tools such as drug-eluting stents have renewed interest in this field. Although conceptually attractive, endovascular therapy for ED presents significant challenges related to unanswered questions such as the prevalence and appropriate diagnostic evaluation of arteriogenic ED, and the safety and feasibility of stent-based therapies in this population. In addition, the evaluation, management, and follow-up of patients with vascular ED require a multi-disciplinary team with specialists in urology, sexual medicine, and vascular medicine. Despite these challenges, the potential for endovascular treatment of these patients remains one of the most exciting areas of investigation in vascular medicine.
勃起功能障碍(ED)是一种重要的临床病症,影响着相当比例的男性。尽管ED有多种病因,但许多病例具有血管基础,这与动脉流入不足、静脉闭塞功能障碍或平滑肌(海绵体组织)松弛异常有关。这些血管异常可单独存在或合并存在。自磷酸二酯酶-5抑制剂(PDE5i)疗法问世以来,大多数情况下ED的初始治疗包括简短的医学评估,随后进行PDE5i疗法试验。然而,高达50%的男性对PDE5i疗法反应不佳并停止治疗。ED的后续治疗越来越具有侵入性,包括阴茎注射血管扩张剂、真空抽吸装置和阴茎植入物。随着临床医生对ED的认识提高以及ED与动脉粥样硬化性血管疾病之间的机制联系日益紧密,对动脉性ED的诊断和治疗重新产生了兴趣。20世纪80年代的先前报告描述了ED患者中存在动脉流入病变,并且有少量报告描述了球囊血管成形术血管重建的可行性。尽管最初取得了临床成功,但对该技术的热情有所下降,可能是因为ED经常因再狭窄和缺乏小血管腔内治疗而复发。最近的研究以及药物洗脱支架等新工具的出现,重新激发了对该领域的兴趣。尽管从概念上讲很有吸引力,但ED的血管内治疗面临重大挑战,涉及一些未解决的问题,如动脉性ED的患病率和适当的诊断评估,以及该人群中基于支架治疗的安全性和可行性。此外,血管性ED患者的评估、管理和随访需要一个由泌尿外科、性医学和血管医学专家组成的多学科团队。尽管存在这些挑战,但对这些患者进行血管内治疗的潜力仍然是血管医学中最令人兴奋的研究领域之一。